NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOGRAFIN-60 is a diatrizoate meglumine injectable contrast agent used for radiographic imaging procedures, particularly renal and urinary tract visualization. It is an iodinated organic compound that enhances radiographic contrast in diagnostic imaging. The drug works by absorbing X-rays, allowing visualization of internal structures during imaging studies.
LOE Approaching
This product faces approaching loss of exclusivity with moderate competitive pressure (30%), indicating a contracting team focus and shift toward cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RENOGRAFIN-60 offers limited career growth potential given the LOE-approaching lifecycle and zero linked job openings. Professionals on this product should view it as a stable, maintenance-oriented role focused on optimizing operations and managing decline rather than driving commercial expansion.
Product ManagerSupply Chain Manager
Worked on RENOGRAFIN-60 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.